Showing 1191-1200 of 1572 results for "".
- New Research Unveils Cellular Pathways to Alzheimer’s and Alternative Brain Aginghttps://reachmd.com/news/new-research-unveils-cellular-pathways-to-alzheimers-and-alternative-brain-aging/2468020/A new study has found an answer for a long-lasting question in aging research - Is Alzheimer’s disease-dementia a form of accelerated aging or is there a different path that can lead us to healthier brain aging? In an international effort, t
- Discovery of Cellular Mechanism to Maintain Brain's Energy Could Benefit Late-Life Brain Healthhttps://reachmd.com/news/discovery-of-cellular-mechanism-to-maintain-brains-energy-could-benefit-late-life-brain-health/2467251/Deletion of A2B receptors in hippocampal astrocytes. Credit: Nature (2024). DOI: 10.1038/s41586-024-07611-w A key mec
- Sylvester Appoints Prominent Oncologist-Researcher to Lead Transplantation and Cellular Therapyhttps://reachmd.com/news/sylvester-appoints-prominent-oncologist-researcher-to-lead-transplantation-and-cellular-therapy/2457224/Newswise — MIAMI, FLORIDA (Feb. 16, 2024) – Prominent oncologist and researcher Damian Green, M.D., will join
- Metabolism and Brain Health: The Potential Impact of Caloric Restrictionhttps://reachmd.com/news/metabolism-and-brain-health-the-potential-impact-of-caloric-restriction/2484659/Boston University School of Medicine reports long-term caloric restriction is linked to cellular changes that may slow brain aging, suggesting benefits for
- Sofwave Ultrasound Technology Remodels Collagen, Elastin, and Hyaluronic Acid in the Skinhttps://reachmd.com/news/sofwave-ultrasound-technology-remodels-collagen-elastin-and-hyaluronic-acid-in-the-skin/2483484/Sofwave’s ultrasound technology is a noninvasive treatment designed to lift sagging skin on the face and neck, improve laxity on the upper arms, and reduce fine lines and wrinkles. It can also address acne scars and the short-term appearance of cellulite. The company hosted an event in New York C
- Decoding Cancer Progression: Mitochondrial Metabolism and Inflammation as Key Playershttps://reachmd.com/news/decoding-cancer-progression-mitochondrial-metabolism-and-inflammation-as-key-players/2483208/Cancer progression, notoriously marked by its resilience and adaptability, continues to challenge clinicians worldwide. Central to this relentless advance are key cellular mechanisms, notably mitochondrial metabolism and inflammation, which are reshaping our understanding of metastatic dyna
- Integrating Weight Management and Oncology: Navigating Immune Challenges Post-Weight Losshttps://reachmd.com/news/integrating-weight-management-and-oncology-navigating-immune-challenges-post-weight-loss/2475638/Exploring the intersections between oncology, metabolic health, and cellular biology, recent insights into weight loss among obese cancer patients suggest potential implications for treatment strategies, though further research is necessary t
- Understanding the Biological Impact of Childhood Maltreatment on Stress and Aginghttps://reachmd.com/news/understanding-the-biological-impact-of-childhood-maltreatment-on-stress-and-aging/2475621/Understanding that childhood maltreatment biologically reshapes stress response and cellular aging challenges pediatricians to integrate trauma-informed care into routine practice. Childhood maltreatment affects up to one in four child
- Emerging Approaches in Glaucoma Treatment: The Role of QLS-111 in Intraocular Pressure (IOP) Managementhttps://reachmd.com/news/emerging-approaches-in-glaucoma-treatment-the-role-of-qls-111-in-intraocular-pressure-iop-management/2475299/Persistent challenges in intraocular pressure control and patient adherence have led to the development of novel agents. QLS-111, which modulates ATP-sensitive potassium channels—proteins that help regulate cellular activity by controlling po
- Biosimilar STEQEYMA Now Approved for All Ustekinumab Dosage Forms, Strengthshttps://reachmd.com/news/Biosimilar-STEQEYMA-Now-Approved-All-Ustekinumab-Dosage-Forms-Strengths/2475172/The US Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, according to a press release from Celltrion, Inc. The additional pre